Related Experiment Videos
Abstract:
Five cases are described in which fear of the possibly hazardous effects of giving amphotericin to patients with kidney disease resulted in death from progressive infection by an amphotericin-sensitive fungus (Cryptococcus neoformans in three cases, Blastomyces dermatitidis in one case, and Histoplasma capsulatum in one case).
Insights
Fear of amphotericin B side effects in kidney disease patients led to fatal fungal infections. Untreated infections by Cryptococcus neoformans, Blastomyces dermatitidis, and Histoplasma capsulatum caused patient deaths.
Area of Science:
- Mycology
- Nephrology
- Infectious Diseases
Background:
- Amphotericin B is a critical antifungal medication.
- Patients with kidney disease often face treatment challenges due to potential nephrotoxicity.
- Fungal infections can be life-threatening, especially in immunocompromised individuals.
Purpose of the Study:
- To report cases where withholding amphotericin B due to renal concerns led to fatal fungal outcomes.
- To highlight the critical balance between managing kidney disease and treating severe fungal infections.
Main Methods:
- Case series review.
- Analysis of five patient cases with severe fungal infections and kidney disease.
- Documentation of treatment decisions and patient outcomes.
Main Results:
- Five patients with kidney disease died from progressive fungal infections (three Cryptococcus neoformans, one Blastomyces dermatitidis, one Histoplasma capsulatum).
- In all cases, amphotericin B was withheld or its use was significantly delayed due to concerns about kidney function.
- The fungal infections were sensitive to amphotericin B, indicating that treatment could have been effective.
Conclusions:
- Withholding or delaying amphotericin B treatment in patients with kidney disease due to fear of side effects can have fatal consequences.
- Careful risk-benefit assessment is crucial when deciding on antifungal therapy in patients with renal impairment.
- Effective management of life-threatening fungal infections should be prioritized, even in the presence of comorbidities like kidney disease.